Genmab | GEN - Passivo Circulante





Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Almirall EUR 323.65M 26.99M 2026-06
Amarin USD 164.2M 15.45M 2026-06
Amgen USD 25.5B 547M 2026-06
argenx SE USD 1.58B 254.81M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
Bayer EUR 32.27B 1.19B 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Demant DKK 12.42B 5B 2026-06
Exelixis USD 361.93M 9.05M 2026-06
Fresenius Medical Care EUR 7.18B 448.03M 2026-06
Genmab DKK 1.14B 38M 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
GN Store Nord DKK 4.81B 2.5B 2026-03
GRIFOLS EUR 2.24B 112M 2026-06
Hikma Pharmaceutical USD 1.45B 603M 2025-12
Insmed USD 438.74M 77.74M 2026-06
Lakefront Biotherapeutics EUR 70.32M 30.1M 2026-06
Lonza CHF 3.57B 421M 2025-12
Merck EUR 8.12B 1.22B 2026-06
Novartis USD 31.75B 374M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
UCB EUR 4.4B 470M 2025-12